340 filings
Page 7 of 17
8-K
c0r01hj
11 Mar 21
Zymeworks Announces Five Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021
12:00am
8-K
ulb7mpl4
24 Feb 21
Zymeworks Reports 2020 Year-End Financial Results
4:21pm
8-K
g5lanf2wx
10 Feb 21
Zymeworks to Participate in Upcoming Investor Conferences and Events
4:31pm
8-K
7t8ppu ci9
10 Feb 21
Zymeworks Expands Commercial Team and Creates New R&D Role
12:00am
8-K
l2i 0g4arvg7d3gu
28 Jan 21
Zymeworks Advances HER2 Bispecific Antibody-Drug Conjugate, ZW49, into Expansion Cohort Stage of Clinical Development
12:00am
8-K
a3g 74ufn77oo
15 Jan 21
Regulation FD Disclosure
4:06pm
8-K
ecgplbuduitq
11 Jan 21
Zymeworks Highlights 2020 Achievements and Announces Corporate Priorities
4:06pm
8-K
chvhjo
7 Jan 21
Zymeworks to Present at J.P. Morgan Healthcare Conference and Host Two
4:05pm
8-K
lwxl58b
10 Dec 20
Zanidatamab Clinical Data Selected for Oral Presentation at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
4:05pm
8-K
vbhpq9h28m
4 Dec 20
Other Events
4:25pm
424B7
ptxw78imq5b2rb
4 Dec 20
Prospectus with selling stockholder info
4:23pm
8-K
oz072ozil2
2 Dec 20
Regulation FD Disclosure
4:05pm
8-K
zg1ex8b wnyiu31x
1 Dec 20
Zymeworks Announces Expansion of Zanidatamab Pivotal Trial in HER2-Amplified Biliary Tract Cancer in Asia in Collaboration with BeiGene
4:10pm
8-K
mk12 ysum7
30 Nov 20
Zymeworks Receives FDA Breakthrough Therapy Designation for HER2-Targeted Bispecific Antibody Zanidatamab in Patients with Biliary Tract Cancer
4:06pm
8-K
0hae2tt3e1g
19 Nov 20
Regulation FD Disclosure
4:17pm
8-K
41j40ugjz49i
16 Nov 20
Regulation FD Disclosure
4:29pm
8-K
m30h 78r0
10 Nov 20
Zymeworks to Present at Upcoming Investor Conferences
4:06pm
8-K
wnnl3rgni
3 Nov 20
Zymeworks Reports 2020 Third Quarter Financial Results
4:17pm